WO2022188046A1 - 载化疗药物/光敏剂的纳米胶束及其制备方法和应用 - Google Patents
载化疗药物/光敏剂的纳米胶束及其制备方法和应用 Download PDFInfo
- Publication number
- WO2022188046A1 WO2022188046A1 PCT/CN2021/079844 CN2021079844W WO2022188046A1 WO 2022188046 A1 WO2022188046 A1 WO 2022188046A1 CN 2021079844 W CN2021079844 W CN 2021079844W WO 2022188046 A1 WO2022188046 A1 WO 2022188046A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- photosensitizer
- solution
- chemotherapeutic drug
- loaded
- drug
- Prior art date
Links
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 230000000973 chemotherapeutic effect Effects 0.000 title abstract description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 120
- 229960004679 doxorubicin Drugs 0.000 claims abstract description 60
- 229960004657 indocyanine green Drugs 0.000 claims abstract description 52
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims abstract description 52
- 239000002245 particle Substances 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 229940044683 chemotherapy drug Drugs 0.000 claims description 47
- 239000002246 antineoplastic agent Substances 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 18
- 238000000502 dialysis Methods 0.000 claims description 17
- 229920000375 Poly(ethylene glycol)-block-poly(ε−caprolactone) methyl ether Polymers 0.000 claims description 10
- 238000005119 centrifugation Methods 0.000 claims description 10
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- 238000009210 therapy by ultrasound Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims description 2
- 239000000693 micelle Substances 0.000 abstract description 56
- 210000004027 cell Anatomy 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 17
- 239000002105 nanoparticle Substances 0.000 abstract description 14
- 210000004881 tumor cell Anatomy 0.000 abstract description 13
- 238000002512 chemotherapy Methods 0.000 abstract description 11
- 230000002195 synergetic effect Effects 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 9
- 238000005286 illumination Methods 0.000 abstract description 8
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 7
- 230000003013 cytotoxicity Effects 0.000 abstract description 7
- 239000006185 dispersion Substances 0.000 abstract description 6
- 238000001126 phototherapy Methods 0.000 abstract description 5
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000005918 in vitro anti-tumor Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 66
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 55
- 239000003814 drug Substances 0.000 description 32
- 229940079593 drug Drugs 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000008367 deionised water Substances 0.000 description 11
- 229910021641 deionized water Inorganic materials 0.000 description 11
- 239000003642 reactive oxygen metabolite Substances 0.000 description 11
- 210000003712 lysosome Anatomy 0.000 description 9
- 230000001868 lysosomic effect Effects 0.000 description 9
- 230000001186 cumulative effect Effects 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 6
- 238000002428 photodynamic therapy Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 5
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000008045 co-localization Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000007626 photothermal therapy Methods 0.000 description 4
- 229920001610 polycaprolactone Polymers 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 3
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000012733 comparative method Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000007578 phototoxic dermatitis Diseases 0.000 description 3
- 231100000018 phototoxicity Toxicity 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002525 ultrasonication Methods 0.000 description 3
- 241000143437 Aciculosporium take Species 0.000 description 2
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000003660 reticulum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- HPZOOQSXPMEJBV-ODCFVKFUSA-N Tirilazad mesylate Chemical compound CS(O)(=O)=O.O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 HPZOOQSXPMEJBV-ODCFVKFUSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002091 nanocage Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920001442 polyethylene glycol-block-polycaprolactone Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Definitions
- the invention relates to nano-medicine technology, in particular to micellar nano-particles with dual therapeutic effects of encapsulating chemotherapeutic drugs (such as doxorubicin) and photosensitizers (such as indocyanine green) and preparation thereof.
- chemotherapeutic drugs such as doxorubicin
- photosensitizers such as indocyanine green
- Chemotherapy drugs are the main treatment methods for cancer, but they have problems such as high toxicity, poor selectivity and strong side effects. Even with the use of drug combination therapy or the combination of surgery and chemotherapy, the curative effect is still poor. By encapsulating the drug with new drug delivery systems such as liposomes and micelles, its curative effect on tumors can be effectively improved.
- Doxorubicin is a widely used antitumor chemotherapy drug, but it has problems such as cardiotoxicity.
- Phototherapy is a new type of tumor treatment method in recent years, including photothermal therapy (PTT) and photodynamic therapy (PDT). Thus play a role in killing cancer cells.
- Indocyanine green (ICG) is currently the only FDA-approved photosensitizer, and light can produce both PTT and PDT therapeutic effects. In the absence of light, the toxicity is extremely low, but it is unstable in water and is easily eliminated in the body.
- the preparation process of these nanoparticles is relatively complicated, the carrier for biological purification requires complex extraction and purification, the chemically synthesized polymer has potential toxicity and complex synthesis steps, and the inorganic nanoparticles have poor biocompatibility and certain toxicity. .
- micellar drug delivery systems are significant. It can improve the bioavailability of poorly soluble drugs, reduce toxic and side effects, improve in vivo stability, prolong circulation time, and have sustained release and passive targeting to tumor cells.
- polyethylene glycol-b-polycaprolactone PEG-PCL as the carrier material to prepare micelles, is conducive to further development and application in clinical practice.
- ICG/DOX micelles with a particle size of 221 nm were prepared at 37°C. However, there are the following defects: 1) The particle size is too large. Usually ⁇ 200nm is more conducive for micelles to avoid the interference of the endothelial reticulum system RES and target the tumor site; 2) The preparation temperature is high, and ICG requires low temperature storage, which will affect the stability.
- the purpose of the present invention is to provide a chemotherapeutic drug/photosensitizer-loaded micelle and its preparation method and application. It is based on the fact that after the chemotherapeutic drug DOX enters the cell, under the synergistic effect of the photosensitizer ICG, the lysosome escapes and enters the nucleus to exert the chemotherapeutic effect. Therefore, nanoparticles encapsulating DOX and ICG are designed.
- the present invention adopts the commercially available carrier material PEG-PCL, and realizes the preparation of ICG/DOX co-encapsulated micelles (ID-M) with a particle size of ⁇ 100 nm at room temperature (25°C), which has the advantages of simple preparation process and preparation conditions.
- a chemotherapeutic drug/photosensitizer-carrying nanomicelle is obtained by encapsulating the chemotherapeutic drug and photosensitizer in a polymer; the hydrated particle size of the chemotherapeutic drug/photosensitizer-carrying nanomicelle is 10 ⁇ 160 nm; preferably, the chemotherapeutic drug is doxorubicin, the photosensitizer is indocyanine green, and the polymer is PEG-PCL.
- the preparation method of the above chemotherapeutic drug/photosensitizer-loaded nanomicelles includes the following steps: mixing chemotherapeutic drug solution, photosensitizer solution, and polymer solution, and then ultrasonically treating to obtain solution A; adding solution A dropwise to water, and ultrasonically treating the solution A. , to obtain solution B; solution B is subjected to dialysis, ultrafiltration and centrifugation to obtain nanomicelles loaded with chemotherapeutic drugs/photosensitizers.
- the invention discloses the application of the above-mentioned chemotherapeutic drug/photosensitizer-loaded nanomicelles in the preparation of tumor therapeutic drugs; the polymer PEG-PCL is selected as a carrier, and the chemotherapeutic drugs and photosensitizers are simultaneously loaded to realize the combination on a nanometer drug-loading platform.
- the dual targeted therapy of chemotherapy toxicity and phototoxicity on tumors plays the role of chemotherapy and/or photodynamic therapy and/or photothermal therapy.
- the preparation of the chemotherapeutic drug/photosensitizer-loaded nanomicelles is carried out at room temperature.
- the solvents are all DMSO (dimethyl sulfoxide).
- the mass ratio of photosensitizer, chemotherapeutic drug and polymer is (0.1-2.0): (0.1-2.0) (0.8-16), preferably (0.5-1.5): (0.5-1.5): (4- 12), most preferably, the mass ratio of photosensitizer to chemotherapeutic drug is 1:1; for example, the mass ratio of photosensitizer, chemotherapeutic drug and polymer is 1:1:6-10.
- the volume ratio of solution A and water is 1:5-15.
- the ultrasonic treatment time is 5-10 minutes.
- the concentration of the chemotherapeutic drug solution is 1 mg/200 ⁇ L; the concentration of the photosensitizer solution is 1 mg/200 ⁇ L; the concentration of the polymer solution is 6-10 mg/200 ⁇ L, preferably 8 mg/200 ⁇ L.
- the rotational speed of the ultrafiltration centrifugation is 3500-6000 r ⁇ min -1 .
- DOXHCl is dissolved in a DMSO solution at room temperature, triethylamine is added for desalting, and the DMSO solution of DOX is formed by ultrasonic treatment;
- ICG is dissolved in DMSO, and the DMSO solution of ICG is formed by ultrasonic treatment;
- the DMSO solution was mixed with the DMSO solution of DOX and the DMSO solution of ICG, added dropwise to water after ultrasonic treatment, and then ultrasonically treated to obtain a mixed solution containing micelles. After ultrafiltration and concentration, micelles containing chemotherapeutic drugs and photosensitizers were obtained.
- Solution ID-M the DMSO solution at room temperature
- triethylamine is added for desalting
- the DMSO solution of DOX is formed by ultrasonic treatment
- ICG is dissolved in DMSO
- the DMSO solution of ICG is formed by ultrasonic treatment
- the DMSO solution was mixed with the DMSO solution of DOX and the DM
- desalted doxorubicin and indocyanine green are co-encapsulated in the hydrophobic cavity of the micelle to obtain micelles with a particle size of not more than 160 nm, which can be used as a new anti-tumor dosage form to enhance the toxicity and target of the drug to tumors.
- tropism play a synergistic effect, reduce systemic side effects, so as to realize the combined treatment of tumors.
- the chemotherapeutic drug is doxorubicin
- the photosensitizer is indocyanine green
- the structural formulas of doxorubicin (DOX) and indocyanine green (ICG) are respectively as follows: .
- the micelle prepared by using the commercially available material PEG-PCL in the present invention is ideal in particle size, light stability, release of the micelle and its killing effect on tumor cells, and has a great application prospect in tumor treatment.
- the mechanism of anti-tumor effect was investigated at the cellular level, and it was confirmed from different aspects such as photothermal, singlet oxygen, cytotoxicity, intracellular drug distribution, etc.
- micellar nanoparticle prepared by the invention has high uptake by tumor cells, has a large killing effect on tumor cells, and has a synergistic effect when combined with chemotherapy/photodynamic therapy under the condition of near-infrared light. Photodynamic therapy damages cells and enhances the effect of chemotherapy. It has high-efficiency, low-toxicity and anti-tumor effects with both chemotherapy and photodynamic therapy, and is a safe and effective new nano preparation.
- Figure 1 Morphological characterization of nanoparticles: TEM image of 1-A micelles; dynamic particle size and distribution of 1-B micelles; Zeta potential map of 1-C micelles.
- Figure 8 Fluorescence images of drug entry into the nucleus before and after micellar irradiation.
- micellar nanoparticles carrying chemotherapeutic drugs/photosensitizers of the present invention are referred to as "micelles" for short.
- the carrier of the present invention is PEG-PCL, specifically PEG 115 - b -PCL 60 , which is commercially available or prepared according to existing conventional methods, such as the article "Research on Environmentally Responsive Nanoparticles for Tumor Imaging and Treatment”; ultrasonic device It is KQ-100DE, Kunshan Ultrasonic Instrument Co., Ltd.
- the ultrasonic power of the embodiment is 100W.
- Example 1 Weigh 8 mg of PEG 115 - b -PCL 60 and dissolve it in 200 mL of DMSO, and ultrasonically for 5 minutes to obtain a polymer solution; weigh 1 mg of ICG, add 200 mL of DMSO, and ultrasonically dissolve for 5 minutes to obtain a photosensitizer solution; Another 1 mg of DOX ⁇ HCl was weighed and dissolved in 200 mL of DMSO, 3 mL of triethylamine was added, and sonicated for 5 minutes to obtain a desalted doxorubicin solution.
- the micelles were prepared by liquid dispersion method. Mix the above three solutions and continue to sonicate for 5 min to obtain a homogeneous solution A. Another 6 mL of deionized water was taken, and solution A was added dropwise to the water (2 drops per second) while sonicating. The dropwise addition was completed, and the initial micellar solution B was obtained by continuing to sonicate for 10 minutes. The entire operation was at room temperature (25 °C). . The solution B was dialyzed (the intercepted molecular weight of the dialysis bag was MWCO: 3500 Da) overnight, and the deionized water was changed every 2 h for dialysis .
- the micelle solution ID-M co-encapsulated with ICG and DOX was obtained, which was a nanomicelle solution loaded with chemotherapeutic drugs/photosensitizers, and was placed for 48 hours without turbidity.
- the encapsulation efficiencies were: ICG 96.1 ⁇ 1.4%, DOX 93.9 ⁇ 3.2%, and the drug loadings were: ICG 17.5 ⁇ 2.4%, DOX 9.1 ⁇ 1.8%.
- the results show that the prepared micelles have a unimodal distribution, the average hydrated particle size is 80.4 ⁇ 14.3 nm (this is the particle size including the surface hydration layer), and the polydispersity coefficient (PDI) is 0.252 ⁇ 0.015, which is beneficial to avoid endothelial reticulum
- the micelles were intercepted to form a long circulation in vivo and played a passive targeting role; as shown in Figure 1-C, the results showed that the micelles were negatively charged, and the Zeta potential was -17.23 ⁇ 0.66 mV. It is beneficial to the circulation of micelles in the body and is not easy to be removed.
- Figure 3 is a graph of cumulative release profiles.
- Table 1 is the zero-order equation, the first-order equation, the Higuchi equation and the Weibull equation, respectively, to fit the data related to the cumulative release of DOX, and obtain the ID-M and free I/D in pH 5.0 PBS and pH 7.4 PBS, respectively. Release behavior results: The cumulative release of free (Free) I/D in pH 7.4 PBS for 24 h was 74.8 ⁇ 7.0 ⁇ g, and in pH 5.0 PBS for 24 h, the cumulative release was 77.3 ⁇ 2.6 ⁇ g; ID-M in pH 7.4 The cumulative release in PBS for 24 h was 23.1 ⁇ 5.2 ⁇ g, and the cumulative release in pH 5.0 PBS for 24 h was 47.5 ⁇ 4.7 ⁇ g.
- Cytotoxicity study of micelles To investigate the toxicity of micelles to tumor cells , logarithmically growing 4T1 cells were seeded in 96-well plates (cell density 5 ⁇ 10 4 ⁇ mL -1 ) and incubated at 37 o C, 5% CO 2 , different concentrations of I/DM and Free I/D were added. After 24 hours of administration, the medium was changed. The light group was treated with a 785 nm laser (1.5 W ⁇ cm -2 , 3 min). After continuing to incubate for 24 h, the medium was replaced, 20 mL of 5 mg ⁇ mL -1 MTT solution was added, and the cells were incubated for 4 h.
- IC 50 (mg ⁇ mL -1 ): IM group 4.72 ⁇ DM group 1.83 ⁇ Free I/D group 1.21 ⁇ ID-M group 0.72.
- the cytotoxicity of ID-M was significantly increased after light exposure, the cell viability was 3.6 ⁇ 0.3 mg ⁇ mL -1 at high concentration (IC 50 decreased by 46.67%), and the cell viability of Free I/D was 15.7 ⁇ 0.2 mg ⁇ mL -1 .
- the cytotoxicity of ID-M was statistically investigated, except that it was different from IM under non-illumination, there was no significant difference with other groups (P>0.05).
- ID-M (>1 mg ⁇ mL -1 ) was significantly different from each group (P ⁇ 0.01), and the anti-tumor effect was significantly enhanced. Moreover, the calculated synergy index CI of ID-M is 0.62, which meets the requirement of the literature that CI ⁇ 0.8 has a significant synergistic therapeutic effect. tumor synergy.
- the non-fluorescent DHE can be oxidized by ROS to ethidium oxide in cells, and ethidium oxide is incorporated into DNA to generate red fluorescence. amount of ROS.
- PBS group 0.4 ⁇ DM group 0.5 ⁇ Free I/D group 1.4 ⁇ IM group 2.4 ⁇ ID-M group 2.6. This indicated that ID-M had the strongest ability to promote ROS production in tumor cells and had the greatest phototoxicity.
- nuclei were stained with 1 mg ⁇ mL -1 Hoechest 33342, incubated and washed three times with PBS, lysosomes were stained with 50 mM Lysotracker DND-26, incubated and washed, added 1 mL of medium, and confocal with laser Microscopy to observe the state of cells in a confocal dish.
- DOX can enter the nucleus of tumor cells to inhibit the synthesis of DNA and RNA, and the effect of chemotherapy can be judged by the amount of DOX entering the nucleus.
- Figure 8 shows the results of DOX entry in ID-M. Nuclei were stained blue, lysosomes were stained green, and DOX showed red fluorescence. The DOX in the nucleus was reflected by the red-blue fluorescence co-localization rate, the DOX in the lysosome was reflected by the red-green fluorescence co-localization rate, and the remaining DOX was in the cytoplasm.
- the high co-localization rate of red and blue indicates that DOX enters the nucleus more and has good anti-tumor effect; the high co-localization rate of red and green indicates that DOX is abundant in lysosomes and has poor effect.
- the co-localization rate it was found that before light exposure, 92.5% of DOX was in the lysosome, 2.7% in the nucleus, and 4.8% in the cytoplasm. 82.7% of the total DOX entered the nucleus at 12 h after illumination, increasing the amount of the drug in the nucleus by 29.6 times. Therefore, the cytotoxicity of ID-M is enhanced by light exposure, which is related to the increase of the amount of drug entering the nucleus, thus confirming that ID-M effectively inhibits tumor cell growth, and there is a synergistic effect of chemotherapy and phototherapy.
- Comparative Example 1 Weigh 8 mg of PEG 115 - b -PCL 60 and dissolve it in 200 mL of DMSO, and ultrasonicate for 5 minutes to obtain a polymer solution; weigh 1 mg of ICG, add 200 mL of DMSO, and ultrasonically dissolve for 5 minutes to obtain a photosensitizer solution; Another 1 mg of DOX ⁇ HCl was weighed and dissolved in 200 mL of DMSO, 3 mL of triethylamine was added, and sonicated for 5 minutes to obtain a desalted doxorubicin solution.
- the micelles were prepared by liquid dispersion method. Mix the above three solutions, drop directly into 6 mL of deionized water without ultrasonication, dropwise under ultrasonication (2 drops per second), complete the dropwise addition, and continue to ultrasonicate for 10 minutes to obtain initial micelle solution B. The entire operation process to room temperature (25°C). The solution B was dialyzed (the intercepted molecular weight of the dialysis bag was MWCO: 3500 Da) overnight, and the deionized water was changed every 2 h for dialysis . After filtration and centrifugation for 10 minutes, the color of the supernatant is very light, and the lower layer has a lot of sediment, and the color is very dark, indicating that the drug is precipitated and the encapsulation fails.
- the micelles were prepared by liquid dispersion method. Mix the above three solutions and continue to sonicate for 5 min to obtain a homogeneous solution A. Take another 6 mL of deionized water, add solution A to the water while sonicating (complete addition within 1 second, not dropwise), and continue to sonicate for 10 minutes to obtain initial micelle solution B. The entire operation is at room temperature (25 °C). The solution B was dialyzed (the intercepted molecular weight of the dialysis bag was MWCO: 3500 Da) overnight, and the deionized water was changed every 2 h for dialysis . After filtration and centrifugation for 10 minutes, the color of the supernatant is very light, and the lower layer has a lot of sediment, and the color is very dark, indicating that the drug is precipitated and the encapsulation fails.
- the micelles were prepared by liquid dispersion method. The whole operation process is room temperature (25 °C), the above three solutions are mixed, and the sonication is continued for 5 min to obtain a uniform solution A. Take another 6 mL of deionized water, add solution A dropwise to the water (2 drops per second) while ultrasonicating, and complete the direct dialysis without ultrasonication (dialysis bag intercepted molecular weight is MWCO: 3500 Da) overnight, every 2 h Change the deionized water once for dialysis, put it in an ultrafiltration centrifuge tube after dialysis, and centrifuge it with ultrafiltration at a speed of 5000 r ⁇ min -1 for 10 minutes. Precipitation, package loading failed.
- the encapsulation effect of the comparative method (3) is better than that of the comparative method (1) and (2), but the three comparative methods are much worse than the drug-carrying effect of the present invention.
- method after ultrafiltration, there is very little sediment in the lower layer.
- micell ID-M can also be prepared by thin film dispersion method.
- the specific scheme is as follows: ICG, DOX and PEG-PCL are co-dissolved in dichloromethane, ultrasonically mixed in a distillation flask, and spin on a rotary evaporator. After drying, distilled water was added dropwise under ultrasonic conditions to dissolve the film on the wall of the distillation flask. After centrifugation at 1500 r ⁇ min -1 for 10 min, the micelle solution was obtained by passing through a 220 nm filter membrane. The particle size of the micellar solution prepared by this method is 35.1 ⁇ 2.8 nm, but it is prone to turbidity. After 10 minutes, the micellar solution appears turbid, indicating instability.
- Comparative Example 3 Dissolve 8 mg of PEG 115 - b -PCL 60 , 1 mg of ICG, and 1 mg of DOX ⁇ HCl in 600 mL of DMSO, add 3 mL of triethylamine, and sonicate for 5 minutes to obtain a homogeneous solution A. Another 6 mL of deionized water was taken, and solution A was added dropwise to the water (2 drops per second) while sonicating. The dropwise addition was completed, and the initial micellar solution B was obtained by continuing to sonicate for 10 minutes. The entire operation was at room temperature (25 °C). .
- the solution B was dialyzed (the intercepted molecular weight of the dialysis bag was MWCO: 3500 Da) overnight, and the deionized water was changed every 2 h for dialysis . Filtration and centrifugation for 10 minutes to obtain the micellar solution ID-M co-encapsulated with ICG and DOX.
- the particle size was analyzed by a laser scattering particle size analyzer, and the average hydrated particle size was 212.4 ⁇ 12.7 nm.
- the existing technology has the problems of high preparation temperature and large particle size of nano-drugs.
- the present invention is designed to prepare particle size at room temperature not exceeding 37 ° C.
- the PEG-PCL smaller than 200nm encapsulates ICG/DOX micelles, giving full play to the synergistic effect of the two treatments, laying the foundation for the further development of new formulations with high efficiency and low toxicity.
- the invention relates to nano-medicine technology, in particular to micellar nanoparticles encapsulating the dual therapeutic effects of chemotherapeutic drugs (such as doxorubicin) and photosensitizers (such as indocyanine green) and preparation thereof, and as a new anti-tumor dosage form, enhancing the The toxicity and targeting of the drug to the tumor can play a synergistic effect, reduce the systemic toxicity and side effects, so as to realize the combined treatment of the tumor.
- chemotherapeutic drugs such as doxorubicin
- photosensitizers such as indocyanine green
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种载化疗药物/光敏剂的纳米胶束及其制备方法和应用,旨在联合光治疗和化疗作用,制备共包载吲哚菁绿(ICG)和阿霉素(DOX)的胶束(ID-M),对制备得到的胶束进行表征并在细胞水平考察其体外抗肿瘤效果。制备的胶束纳米粒,条件温和,粒径较小、分散均匀、形态圆整,具有良好的化学稳定性、光照稳定性,在近红外光的照射下具有较高的活性氧产生能力,此外在细胞实验中,该纳米粒对肿瘤细胞具有较强的细胞毒性和良好的细胞摄取,发挥协同增效的作用,降低毒副作用,实现了光化疗联合***。
Description
本发明涉及纳米药物技术,具体为包载化疗药物(如阿霉素)和光敏剂(如吲哚菁绿)的双重治疗效果的胶束纳米粒及其制备。
癌症是全球性的重大疾病,化疗药物是癌症的主要治疗手段,但其具有毒性大,选择性差,副作用强等问题。即使采用药物联合治疗或是手术与化疗联合应用等方法,疗效仍旧欠佳。通过将药物用脂质体、胶束等新型给药体系包载可有效改善其对肿瘤的疗效。
阿霉素(DOX)是广泛应用的抗肿瘤化疗药物,但有心脏毒性等问题。光治疗是近年来新型的肿瘤治疗方法,包括光热治疗(photothermal therapy, PTT)和光动力治疗(photodynamic therapy, PDT),其主要原理是光敏剂受激发光照射后,会产生热和活性氧,从而起到杀伤癌细胞的作用。吲哚菁绿(ICG)是目前唯一被FDA批准上市的光敏剂,光照可同时产生PTT和PDT治疗作用。而在无光照时毒性极低,但其在水中不稳定,在体内易被清除。
现有研究运用不同类型的载体对ICG和DOX进行共包载,包括:生物提纯的载体(如人血清白蛋白、红细胞膜等)、经过化学合成的载体(响应性聚合物、修饰靶头的聚合物等)以及无机纳米粒载体(介孔二氧化硅、金纳米笼、MOF结构等)形成不同的给药***,粒径大多数在100-200 nm之间,能在一定的条件下达到理想的释放效果以及对肿瘤细胞的杀伤的作用。但是,这些纳米粒的制备工艺相对复杂,生物提纯的载体需要复杂的提取和纯化、化学合成的高分子聚合物会有潜在毒性且合成步骤复杂、无机纳米粒生物相容性差且有一定的毒性。
胶束给药***优势显著。它能够提高难溶性药物的生物利用度,降低毒副作用,改善体内稳定性,延长循环时间,具有缓释作用和对肿瘤细胞的被动靶向作用。运用合成工艺成熟且已经上市的聚合物材料,聚乙二醇-b-聚己内酯PEG-PCL作为载体材料制备胶束,有利于进一步研发运用于临床。现有技术在37℃条件下制得粒径221nm的ICG/DOX胶束。但是,存在以下缺陷:1)粒径偏大。通常<200nm更有利于胶束避开内皮网状***RES的干扰,靶向到达肿瘤部位;2)制备温度偏高,ICG要求低温保存,该温度会影响稳定性。
为解决以上技术问题,本发明的目的是提供一种载化疗药物/光敏剂的胶束及其制备方法和应用。它基于化疗药物DOX进入细胞后,在光敏剂ICG的协同作用下,实现溶酶体逃逸,进入到细胞核内发挥化疗效果,故设计包载DOX、ICG的纳米粒,1)在纳米粒的测定中,采用荧光分光光度计测定DOX的含量,紫外-可见分光光度计测定ICG的含量,保证结果可靠;2)体外和细胞实验,用游离药物以及单独包载ICG和DOX的胶束作对照,仍可得到可靠的结果。因此,本发明采用市售载体材料PEG-PCL,实现了在室温(25℃)制备出粒径≤100 nm的ICG/DOX共包载胶束(ID-M),具有制备工艺简单、制备条件温和、粒径可控、生物相容性好、肿瘤靶向性和滞留性好等优势,整合了光化疗治疗手段实现高效杀伤肿瘤细胞、有效结合光治疗促进化疗药物进核发挥疗效的纳米胶束的制备和应用。
本发明采用如下技术方案:一种载化疗药物/光敏剂的纳米胶束,由聚合物包载化疗药物和光敏剂得到;所述载化疗药物/光敏剂的纳米胶束的水合粒径为10~160 nm;优选的,化疗药物为阿霉素,光敏剂为吲哚菁绿,聚合物为PEG-PCL。
上述载化疗药物/光敏剂的纳米胶束,其制备方法包括以下步骤,将化疗药物溶液、光敏剂溶液、聚合物溶液混合,然后超声处理,得到溶液A;将溶液A滴加入水中,超声处理,得到溶液B;溶液B经过透析、超滤离心,得到载化疗药物/光敏剂的纳米胶束。
本发明公开了上述载化疗药物/光敏剂的纳米胶束在制备肿瘤治疗药物中的应用;选用聚合物PEG-PCL作为载体,同时包载化疗药物和光敏剂,实现在一个纳米载药平台结合化疗毒性和光毒性对肿瘤的双重靶向治疗作用,起到化疗和/或光动力治疗和/或光热治疗的作用。
本发明中,载化疗药物/光敏剂的纳米胶束的制备在室温下进行。
本发明中,化疗药物溶液、光敏剂溶液、聚合物溶液中,溶剂都是DMSO(二甲基亚砜)。
本发明中,光敏剂、化疗药物、聚合物的质量比为(0.1~2.0)∶(0.1~2.0)(0.8~16),优选为(0.5~1.5)∶(0.5~1.5)∶(4~12),最优选的,光敏剂、化疗药物的质量比为1∶1;比如,光敏剂、化疗药物、聚合物的质量比为1∶1∶6~10。
本发明中,溶液A、水的体积比为1∶5~15。
本发明中,超声处理的时间为5~10分钟。
本发明中,化疗药物溶液的浓度为1mg/200μL;光敏剂溶液的浓度为1mg/200μL;聚合物溶液的浓度为6~10mg/200μL,优选8mg/200μL。
本发明中,超滤离心的转速为3500~6000 r·min
-1。
本发明在室温下,将DOXHCl溶于DMSO溶液中,加入三乙胺脱盐,超声处理形成DOX的DMSO溶液;将ICG溶于DMSO中,超声处理,形成ICG的DMSO溶液;将PEG-PCL的DMSO溶液与DOX的DMSO溶液、ICG的DMSO溶液混合,超声处理后滴加入水中,再超声处理,得到含胶束的混合溶液,经超滤浓缩后得到包载化疗药物和光敏剂的胶束溶液ID-M。本发明中将脱盐阿霉素和吲哚菁绿共同包载在胶束的疏水性空腔中,得到粒径不超过160nm的胶束,作为抗肿瘤新药剂型,增强药物对肿瘤的毒性和靶向性,发挥协同增效作用,降低全身毒副作用,从而实现肿瘤的联合治疗。
本发明采用市售材料PEG-PCL制备的胶束,粒径、光照稳定性、胶束的释放以及其对肿瘤细胞的杀伤作用,均较为理想,在肿瘤治疗中具有较大的应用前景。并且在细胞层面考察抗肿瘤效应的机制,从光热、单线态氧、细胞毒性、胞内的药物分布等不同方向证实胶束包载两种药物,具有抗肿瘤协同作用。
本发明制备的胶束纳米粒肿瘤细胞摄取量高,对肿瘤细胞的杀伤作用大,在近红外光照条件下联合化疗/光动力治疗具有协同作用,光动力治疗损伤细胞并增强了化疗效果,展示了兼具化疗和光动力治疗的高效低毒抗肿瘤作用,是安全有效的纳米新制剂。
图1纳米粒的形态表征图:1-A胶束的透射电镜图;1-B胶束的动态粒径及其分布图;1-C胶束的Zeta电位图。
图2胶束的光照稳定性图。
图3胶束的药物累计释放量图。
图4乳腺癌细胞4T1对胶束的摄取量图。
图5胶束对4T1细胞的细胞毒性结果图。
图6胶束光照促进细胞内产生活性氧荧光图。
图7胶束光照促进细胞溶酶体膜破坏图。
图8胶束光照前后药物入核情况荧光图。
下面结合附图和实施例,对本发明的具体实施方式作进一步详细描述。以下实施例用于说明本发明,但不局限于此。本发明载化疗药物/光敏剂的胶束纳米粒,简称“胶束”。本发明的载体为PEG-PCL,具体为PEG
115-
b-PCL
60,市售或者根据现有常规方法制备,比如“用于肿瘤成像与治疗的环境响应性纳米粒的研究”一文;超声装置为KQ-100DE,昆山市超声仪器有限公司,实施例超声功率为100W。
实施例一:称取8 mg PEG
115-
b-PCL
60溶于200 mL DMSO中,超声5分钟得到聚合物溶液;称取ICG 1 mg,加200 mL DMSO,超声5分钟溶解得光敏剂溶液;另称取1 mg DOX·HCl溶于200 mL DMSO中,加3 mL三乙胺,超声5分钟得到脱盐阿霉素溶液。
胶束的制备:采用液中分散法制备胶束。将上述三份溶液混合,继续超声5 min得均匀的溶液A。另取6 mL去离子水,边超声边将溶液A逐滴加到水中(每秒2滴),滴加完成,继续超声10分钟得胶束初溶液B,整个操作过程为室温(25 ℃)。将溶液B透析(透析袋拦截分子量为MWCO:3500 Da)过夜,每隔2 h换一次去离子水进行透析,透析完成后置于超滤离心管中,以5000
r·min
-1的转速超滤离心10分钟,得到ICG及DOX共包载的胶束溶液ID-M,为载化疗药物/光敏剂的纳米胶束溶液,放置48小时,未见混浊。
根据常规方法计算载药量与包封率,比如载药量(drug loading, DL)依据公式DL%=(游离药物的质量+包裹药物的质量)/(游离药物的质量+包裹药物的质量+载体的质量)x100%进行计算,包封率(entrappment efficiency, EE)依据公式EE%=(包载药物的质量)/(游离药物的质量+包载药物的质量)x100%计算。包封率分别为:ICG 96.1±1.4%,DOX 93.9±3.2%,载药量分别为:ICG 17.5±2.4%,DOX 9.1±1.8%。
另外,上述方法中不加ICG、不加DOX或者不加ICG/DOX,同法制备得到单包载ICG胶束溶液(I-M)、单包载DOX胶束溶液(D-M)及空白胶束溶液(B-M)。
胶束的形态表征:( 1 )胶束的透射电镜表征:取20 μL胶束溶液ID-M滴到铜网碳支持膜上,放入干燥器中挥干水分后用120
kV透射电镜(TEM)观察形态。结果如图1-A。结果表明,制备的纳米粒为规整的圆形,粒径为41.0±5.9
nm。
( 2 )胶束的粒径及其分布表征:取新制胶束溶液ID-M,常规稀释后,超声10 min混匀,取1 mL采用激光散射粒径仪对其粒径及分布进行分析。结果如图1-B。结果表明制得的胶束为单峰分布,平均水合粒径为80.4±14.3 nm(此为包含表面水化层的粒径),多分散系数(PDI)为0.252±0.015,有利于避免内皮网状细胞拦截,形成体内长循环,发挥被动靶向作用;如图1-C,结果表明胶束带有负电荷,Zeta电位为-17.23±0.66 mV。有利于胶束在体内的循环,不易被清除。
胶束的光热稳定性考察:取ICG浓度为10 mg×mL
-1的ID-M胶束溶液0.5 mL,以785 nm激光器(1.5 W×cm
-2)光照5 min,每30 s记录一次溶液温度。关闭激光器,待溶液冷却到室温后,以相同条件再次照射5 min,如此光照去光照反复5次。结果如图2,前三次升温稳定达到36.5±1.1
oC(温差:11.5±1.1
oC),光热稳定性良好。
胶束的体外释放行为考察:用透析法考察。分别将80 mg×mL
-1DOX浓度的ID-M、游离 I/D溶液置于透析袋(MWCO:3500 Da)后,放入模拟生理环境和肿瘤细胞溶酶体内环境的pH 7.4 PBS、pH
5.0 的PBS中,在37
oC、120 r×min
-1的恒温震荡仪中透析。分别于不同时间点取释放液,并补充等体积新鲜缓冲液,用荧光法检测缓冲液中DOX的含量,计算累积释放量、考察释放规律。游离ICG/DOX(游离 I/D)是先将两者混溶于一定体积的DMSO中,在超声条件下注入去离子水形成澄清的体系,DMSO在水中的含量为5%。
图3为累积释放曲线图。表1为分别采用零级方程、一级方程、Higuchi方程和Weibull方程,对DOX累计释放量相关数据进行拟合,得到ID-M、游离I/D分别在pH 5.0 PBS、pH
7.4 PBS中的释放行为结果:游离(Free) I/D在pH 7.4 PBS中24 h的累计释放量为74.8±7.0 μg,pH 5.0 PBS中24 h的累计释放量为77.3±2.6 μg;ID-M在pH 7.4 PBS中24 h的累计释放量为23.1±5.2μg,pH 5.0 PBS中24 h的累计释放量为47.5±4.7 μg。胶束药物和游离药物的释放规律拟合后都符合Weibull方程,药物经胶束包载后缓释作用显著,在模拟正常生理环境的pH 7.4 PBS中的释放非常缓慢,而模拟肿瘤细胞溶酶体内环境pH
5.0 PBS使释放加快,T
1/2从105.36 h缩短至22.85 h,缩短了78.3%。说明ID-M可将DOX靶向输送至肿瘤细胞溶酶体处释放,并发挥作用,而在达到靶部位前药物泄漏少。
细胞摄取量的考察:取对数生长的4T1细胞接种于6孔板中(细胞密度 5´10
5个/孔),置于细胞培养箱中(37
oC,5% CO
2)孵育24 h后,分别加入ICG浓度为8 mg×mL
-1的ID-M、对照用游离ICG+DOX混合物(Free I/D),孵育24 h并用PBS清洗细胞后,将细胞吹打分散在PBS中并计数;超声(500 W,120 s)粉碎细胞,取细胞粉碎液加入DMSO,细胞摄入的ICG和DOX的浓度分别用紫外分光光度计和荧光分光光度计来检测。图4显示药物经胶束包载后的ID-M,可使细胞摄取ICG的量为1.72±0.02 μg/10
6个细胞,摄取DOX的量为1.38±0.11 μg/10
6个细胞,显著高于游离ICG摄取量0.82±0.02 μg/10
6个细胞,游离DOX的量0.54±0.03μg/10
6个细胞;DOX的摄取量增加了2.0倍,ICG的摄取量增加了1.6倍。而且细胞摄取量ID-M组与D-M组、I-M组的对应药物几乎一致,ID-M保持了各单包载胶束的优势。
胶束的细胞毒性考察:为考察胶束对肿瘤细胞的毒性
,取对数生长的4T1细胞接种于96孔板中(细胞密度5´10
4个×mL
-1)孵育37
oC,5% CO
2,加入不同浓度的I/D-M、Free I/D,给药24 h后,更换培养基,光照组用785 nm激光器(1.5 W×cm
-2、3 min)。继续孵育24 h后,更换培养基,加入20 mL 5 mg×mL
-1 MTT溶液,孵育4 h。吸出孔板中的液体,加入DMSO,振荡混匀,用酶标仪检测490 nm处的吸光度值(Abs)。计算细胞存活率(%)= Abs
实验组/Abs
对照组´100%;将各组细胞存活率及给药浓度输入IC
50计算器,计算得到IC
50值;并且,计算协同指数CI,CI=+,当CI < 0.8,协同治疗效果显著。
从图5的细胞存活率可知,空白胶束对细胞几乎没有毒性。通过计算,得到结果为,光照前,只有DOX化疗作用,ID-M组高浓度下细胞存活率为24.8±2.2 mg×mL
-1,Free I/D的细胞存活率为34.5±8.5 mg×mL
-1,计算得到IC
50(mg×mL
-1):I-M在给药浓度范围内几乎没有毒性<<Free I/D组3.02<<D-M组1.44≈ID-M组1.35。光照后,可兼有DOX化疗和ICG光毒性作用,IC
50(mg×mL
-1):I-M组4.72<<D-M组1.83<Free I/D组1.21<<ID-M组0.72。光照后ID-M的细胞毒性显著增加,高浓度下细胞存活率为3.6±0.3
mg×mL
-1(IC
50降低了46.67%),Free I/D的细胞存活率为15.7±0.2 mg×mL
-1。同时,ID-M的细胞毒性经统计学考察,非光照下除与I-M有差异外,与其余各组均无显著性差异(P>0.05)。但光照下ID-M(>1 mg×mL
-1)与各组均有极为显著的差异(P<0.01),抗肿瘤作用增效显著。并且,计算得到ID-M的协同指数CI为0.62,符合文献对CI<0.8即有显著协同治疗效果的要求,说明本文联合两种治疗手段,ICG和DOX共包载ID-M具有显著的抗肿瘤协同作用。
促进细胞内产生活性氧的考察:将对数生长期的4T1细胞接种于12孔板中,加入用培养基稀释的ICG浓度为4 mg×mL
-1的I-D、D-M、ID-M、Free I/D,孵育24 h,用无血清培养基洗三次,光照组(785 nm,1.5 W×cm
-2)与非光照组一起加入DHE孵育30 min。用荧光显微镜观察红色荧光。ICG促进产生活性氧(ROS)是其发挥杀伤细胞作用的重要指标。以荧光探针二氢乙啶DHE检测ROS,利用没有荧光的DHE可在细胞内能被ROS氧化成氧化乙啶,氧化乙啶掺入DNA中产生红色荧光,用荧光显微镜观察荧光强弱判断胞内ROS的量。如活性氧ROS荧光检测结果(图6)可见,荧光强度(a.u.),光照前:PBS组0.2=Free I/D组0.2=I-M组0.2<D-M组0.3=ID-M组0.3,各组几乎都只有非常微弱的荧光。光照后:PBS组0.4<D-M组0.5<<Free I/D组1.4<<I-M组2.4<ID-M组2.6。说明ID-M促进肿瘤细胞内产生ROS的能力最强,光毒性最大。
破坏细胞溶酶体膜促进药物进入细胞核的考察:用吖啶橙(AO)荧光探针法检测,将4T1细胞接种于24孔板中,分别加入用培养基稀释的ICG浓度为4 mg×mL
-1的ID-M、Free I/D,I-M,D-M溶液孵育24 h后,光照组(785 nm,1.5 W×cm
-2)与非光照组一起加入10 mg×mL
-1的AO孵育30 min。用荧光显微镜观察孔板内细胞的不同荧光。吖啶橙(AO)荧光探针可透过活细胞膜,进入细胞内偏酸性的溶酶体中被质子化产生红色荧光,而在细胞核等偏中性的环境中则呈现绿色荧光。从图7荧光显微镜观察结果可知,光照前各组破膜率比较接近。光照后含有ICG的样品组都有红色荧光减弱,绿色荧光增强的现象。统计后发现,光照后30
min各组的溶酶体破膜率分别为:PBS组1.3%
< D-M组5.3% < Free I/D组41.3% < I-M组100%
= ID-M组100%。因此,光照后ICG产生ROS,促使溶酶体破膜,进而促进ID-M中的DOX进入细胞核发挥杀死肿瘤细胞的作用。
光照促进化疗药物进入细胞核的协同作用考察:将4T1细胞接种于共聚焦培养皿中,加入用培养基稀释的ICG浓度为4 mg×mL
-1的ID-M溶液,孵育6 h后,光照(785 nm,1.5 W×cm
-2)后继续孵育6 h。与非光照组一起,用1 mg×mL
-1 Hoechest 33342染核,孵育并用PBS洗三次,用50 mM的Lysotracker
DND-26染溶酶体,孵育洗涤,加入1 mL培养基,用激光共聚焦显微镜观察共聚焦培养皿中的细胞状态。
DOX可进入肿瘤细胞核抑制DNA与RNA的合成,以其进核量判断化疗作用。图8为ID-M中DOX进核结果。细胞核均被染成蓝色,溶酶体被染成绿色,DOX显红色荧光。细胞核中的DOX由红蓝荧光共定位率反映,溶酶体中的DOX由红绿荧光共定位率反映,余下的DOX则在胞浆中。红蓝共定位率高,说明DOX进入细胞核多,抗肿瘤效果好;红绿共定位率高,说明DOX在溶酶体中多,效果差。结果,考察共定位率发现,光照前,DOX有92.5%在溶酶体中,2.7%在细胞核中,4.8%在胞浆中;光照后不同时间,DOX从溶酶体逃逸进入细胞核的量逐渐提升,到光照后12 h占总量82.7%的DOX进入细胞核,使核内药量增加29.6倍。因此,ID-M的细胞毒性因光照而提高,与进入细胞核的药量增加有关,从而证实了ID-M高效抑制肿瘤细胞生长,存在化疗和光治疗的协同作用。
对比例一:称取8 mg PEG
115-
b-PCL
60溶于200 mL DMSO中,超声5分钟得到聚合物溶液;称取ICG 1 mg,加200 mL DMSO,超声5分钟溶解得光敏剂溶液;另称取1 mg DOX·HCl溶于200 mL DMSO中,加3 mL三乙胺,超声5分钟得到脱盐阿霉素溶液。
(1)采用液中分散法制备胶束。将上述三份溶液混合,不进行超声直接滴入6 mL去离子水中,滴加在超声下进行(每秒2滴),滴加完成,继续超声10分钟得胶束初溶液B,整个操作过程为室温(25 ℃)。将溶液B透析(透析袋拦截分子量为MWCO:3500 Da)过夜,每隔2 h换一次去离子水进行透析,透析完成后置于超滤离心管中,以5000 r·min
-1的转速超滤离心10分钟,上清颜色很浅,下层沉淀很多,颜色很深,表明药物析出,包载失败。
(2)采用液中分散法制备胶束。将上述三份溶液混合,继续超声5 min得均匀的溶液A。另取6 mL去离子水,边超声边将溶液A加入到水中(1秒内加完,非滴加),继续超声10分钟得胶束初溶液B,整个操作过程为室温(25 ℃)。将溶液B透析(透析袋拦截分子量为MWCO:3500 Da)过夜,每隔2 h换一次去离子水进行透析,透析完成后置于超滤离心管中,以5000
r·min
-1的转速超滤离心10分钟,上清颜色很浅,下层沉淀很多,颜色很深,表明药物析出,包载失败。
(3)采用液中分散法制备胶束。整个操作过程为室温(25 ℃),将上述三份溶液混合,继续超声5 min得均匀的溶液A。另取6 mL去离子水,边超声边将溶液A逐滴加到水中(每秒2滴),滴加完成不超声直接透析(透析袋拦截分子量为MWCO:3500 Da)过夜,每隔2 h换一次去离子水进行透析,透析完成后置于超滤离心管中,以5000 r·min
-1的转速超滤离心10分钟,上清颜色很浅,下层沉淀很多,颜色很深,表明药物析出,包载失败。
相对而言,第(3)种对比方法的包载效果较(1)(2)对比方法要好,但是这三个对比方法都较本发明的载药效果差得多,本发明实施例一的方法,超滤后,下层沉淀非常少。
对比例二:采用薄膜分散法也可以制备胶束ID-M,具体方案如下:将ICG、DOX以及PEG-PCL共同溶解在二氯甲烷中,超声混合在蒸馏烧瓶中,在旋转蒸发仪上旋干,后在超声条件下逐滴加入蒸馏水,将蒸馏瓶壁上的薄膜溶解,1500
r·min
-1离心10 min后,过220 nm滤膜得到胶束溶液。此方法制备的胶束溶液粒径为35.1±2.8
nm,但易产生浑浊,放置10分钟,胶束溶液出现浑浊,说明不稳定。
对比例三:将8 mg PEG
115-
b-PCL
60、1 mg ICG、1 mg DOX·HCl溶于600 mL DMSO中,加3 mL三乙胺,超声5分钟得到均匀的溶液A。另取6 mL去离子水,边超声边将溶液A逐滴加到水中(每秒2滴),滴加完成,继续超声10分钟得胶束初溶液B,整个操作过程为室温(25 ℃)。将溶液B透析(透析袋拦截分子量为MWCO:3500 Da)过夜,每隔2 h换一次去离子水进行透析,透析完成后置于超滤离心管中,以5000
r·min
-1的转速超滤离心10分钟,得到ICG及DOX共包载的胶束溶液ID-M,采用激光散射粒径仪对其粒径进行分析,平均水合粒径为212.4±12.7nm。
现有技术存在制备温度高、纳米药物粒径偏大的问题,为更好地实现光敏剂ICG和化疗药DOX的联合应用,本发明设计在不超过37
oC的室温条件下,制备粒径小于200nm的PEG-PCL包载ICG/DOX胶束,充分发挥两种治疗手段的协同作用,为进一步研发高效低毒新型制剂奠定基础。本发明涉及纳米药物技术,具体为包载化疗药物(如阿霉素)和光敏剂(如吲哚菁绿)的双重治疗效果的胶束纳米粒及其制备,并作为抗肿瘤新药剂型,增强药物对肿瘤的毒性和靶向性,发挥协同增效作用,降低全身毒副作用,从而实现肿瘤的联合治疗。
Claims (10)
- 一种载化疗药物/光敏剂的纳米胶束,其特征在于,由聚合物包载化疗药物和光敏剂得到;所述载化疗药物/光敏剂的纳米胶束的水合粒径为10~160 nm。
- 根据权利要求1所述载化疗药物/光敏剂的纳米胶束,其特征在于,化疗药物为阿霉素,光敏剂为吲哚菁绿,聚合物为PEG-PCL。
- 根据权利要求1所述载化疗药物/光敏剂的纳米胶束,其特征在于,将化疗药物溶液、光敏剂溶液、聚合物溶液混合,然后超声处理,得到溶液A;将溶液A滴加入水中,超声处理,得到溶液B;溶液B经过透析、超滤离心,得到载化疗药物/光敏剂的纳米胶束。
- 权利要求1所述载化疗药物/光敏剂的纳米胶束在制备肿瘤治疗药物中的应用。
- 权利要求1所述载化疗药物/光敏剂的纳米胶束的制备方法,其特征在于,包括以下步骤,将化疗药物溶液、光敏剂溶液、聚合物溶液混合,然后超声处理,得到溶液A;将溶液A滴加入水中,超声处理,得到溶液B;溶液B经过透析、超滤离心,得到载化疗药物/光敏剂的纳米胶束。
- 根据权利要求5所述载化疗药物/光敏剂的纳米胶束的制备方法,其特征在于,载化疗药物/光敏剂的纳米胶束的制备在室温下进行;光敏剂、化疗药物、聚合物的质量比为(0.1~2.0)∶(0.1~2.0)∶(0.8~16)。
- 根据权利要求5所述载化疗药物/光敏剂的纳米胶束的制备方法,其特征在于,溶液A、水的体积比为1∶5~15。
- 根据权利要求5所述载化疗药物/光敏剂的纳米胶束的制备方法,其特征在于,超声处理的时间为5~10分钟。
- 根据权利要求5所述载化疗药物/光敏剂的纳米胶束的制备方法,其特征在于,超滤离心的转速为3500~6000 r·min -1。
- 根据权利要求5所述载化疗药物/光敏剂的纳米胶束的制备方法,其特征在于,化疗药物为阿霉素,光敏剂为吲哚菁绿,聚合物为PEG-PCL。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/079844 WO2022188046A1 (zh) | 2021-03-09 | 2021-03-09 | 载化疗药物/光敏剂的纳米胶束及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/079844 WO2022188046A1 (zh) | 2021-03-09 | 2021-03-09 | 载化疗药物/光敏剂的纳米胶束及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022188046A1 true WO2022188046A1 (zh) | 2022-09-15 |
Family
ID=83227325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/079844 WO2022188046A1 (zh) | 2021-03-09 | 2021-03-09 | 载化疗药物/光敏剂的纳米胶束及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022188046A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103864921A (zh) * | 2014-01-16 | 2014-06-18 | 苏州大学 | 双重靶向治疗癌症的叶酸-阿霉素免疫制剂及其制备方法 |
CN108478531A (zh) * | 2018-05-21 | 2018-09-04 | 中国医学科学院生物医学工程研究所 | 叶酸靶向还原敏感载药聚合物纳米胶束及其制备方法和应用 |
CN111518545A (zh) * | 2020-04-20 | 2020-08-11 | 苏州大学 | 高稳定性近红外二区纳米荧光探针及其制备方法和应用 |
-
2021
- 2021-03-09 WO PCT/CN2021/079844 patent/WO2022188046A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103864921A (zh) * | 2014-01-16 | 2014-06-18 | 苏州大学 | 双重靶向治疗癌症的叶酸-阿霉素免疫制剂及其制备方法 |
CN108478531A (zh) * | 2018-05-21 | 2018-09-04 | 中国医学科学院生物医学工程研究所 | 叶酸靶向还原敏感载药聚合物纳米胶束及其制备方法和应用 |
CN111518545A (zh) * | 2020-04-20 | 2020-08-11 | 苏州大学 | 高稳定性近红外二区纳米荧光探针及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
ZHU GUANCHEN, WANG KAIKAI, QIN HAIXIANG, ZHAO XIAOZHI, CHEN WEI, XU LINFENG, CAO WENMIN, GUO HONGQIAN: "Internal cross-linked polymeric nanoparticles with dual sensitivity for combination therapy of muscle-invasive bladder cancer", JOURNAL OF NANOBIOTECHNOLOGY, vol. 18, no. 1, 1 December 2020 (2020-12-01), XP055964967, DOI: 10.1186/s12951-020-00686-3 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Light-activatable dual-source ROS-responsive prodrug nanoplatform for synergistic chemo-photodynamic therapy | |
Yang et al. | Near-infrared light triggered liposomes combining photodynamic and chemotherapy for synergistic breast tumor therapy | |
Bazylińska et al. | Nanoemulsion-templated multilayer nanocapsules for cyanine-type photosensitizer delivery to human breast carcinoma cells | |
Ding et al. | Tumor targeted nanostructured lipid carrier co-delivering paclitaxel and indocyanine green for laser triggered synergetic therapy of cancer | |
CN112999153B (zh) | 载化疗药物/光敏剂的纳米胶束及其制备方法和应用 | |
Guo et al. | Direct site-specific treatment of skin cancer using doxorubicin-loaded nanofibrous membranes | |
CN111617246B (zh) | 一种纯光敏剂自组装纳米粒及其制备和应用 | |
Yang et al. | NIR-activated self-sensitized polymeric micelles for enhanced cancer chemo-photothermal therapy | |
CN109718207A (zh) | 化疗药-光敏剂共组装纳米粒及其构建 | |
CN108653733A (zh) | 具有气泡生成功能的双载蒽环类药物及光敏剂的聚合物囊泡与制备 | |
CN113350503B (zh) | 一种无载体杂合纳米组装体及其制备方法与应用 | |
Xu et al. | Self-assembled nanoparticles based on supramolecular-organic frameworks and temoporfin for an enhanced photodynamic therapy in vitro and in vivo | |
CN113633625B (zh) | 一种杂膜负载氧化磷酸化抑制剂的纳米药物及其制备方法 | |
CN108329404B (zh) | 一种ir-780碘化物-壳聚糖硬脂酸嫁接物及制备与应用 | |
CN107126561B (zh) | 一种可实现化疗和ptt/pdt联合治疗的抗肿瘤协同组合物及其应用 | |
CN110448699B (zh) | 包含功能性多肽修饰七甲川花菁素类染料的肿瘤细胞核靶向载药纳米粒子及制备方法 | |
CN113648401B (zh) | 一种蛋白酶体抑制增敏光动力治疗的杂化纳米组装体及其制备与应用 | |
CN107007550B (zh) | 一种氧化还原响应性两亲性共聚物及其制备方法和应用 | |
Adriouach et al. | Squalene-PEG: Pyropheophorbide-a nanoconstructs for tumor theranostics | |
CN113384698B (zh) | 一种协同化疗/声-光动力治疗的自组装纳米药物及其应用 | |
Yang et al. | Oxidation-strengthened disulfide-bridged prodrug nanoplatforms with cascade facilitated drug release for synergetic photochemotherapy | |
CN113827553B (zh) | 用于肿瘤光动力学治疗的瘤内注射给药的酞菁锌在位凝胶及其制备方法 | |
CN113041359B (zh) | 一种谷胱甘肽响应性抗骨肉瘤前药纳米粒子及其制备方法和用途 | |
WO2022188046A1 (zh) | 载化疗药物/光敏剂的纳米胶束及其制备方法和应用 | |
CN107028882A (zh) | 一种物理包裹的肿瘤靶向纳米递药***及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21929527 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21929527 Country of ref document: EP Kind code of ref document: A1 |